Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2025-10-29 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
关于调整公司第四届董事会专门委员会委员的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding adjustments to the members of the company's fourth board of directors' specialized committees. It details changes in committee membership, including the strategic committee, nomination committee, audit committee, and remuneration and assessment committee. The document includes references to company laws and internal rules but does not contain financial data, earnings, or report publication information. It is clearly about board/management changes, specifically committee member adjustments. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused solely on board committee changes, confirming this classification.
2025-10-29 Chinese
第四届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 16th meeting of the 4th Board of Directors of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting's attendance, agenda items, voting results, and compliance with legal requirements. It references the approval of the company's 2025 third quarter report but does not contain the report itself, only stating that the report is published on the Beijing Stock Exchange website. The document is short (1151 characters) and serves as a meeting resolution announcement rather than a full financial report or detailed management discussion. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2025-10-29 Chinese
国浩律师（南京）事务所关于江苏德源药业股份有限公司2025年第二次临时股东会之法律意见书
Regulatory Filings Classification · 85% confidence The document is a law firm’s legal opinion (法律意见书) on the convening procedures, attendees’ qualifications, voting process, and results of Jiangsu Deyuan Pharmaceutical Co.’s 2025 second extraordinary shareholders’ meeting. It is not an AGM presentation, proxy materials, or an earnings report; rather it is a compliance/legal opinion document that certifies meeting procedures and vote counts. There is no specific category for legal opinion letters, so under the fallback “Regulatory Filings (RNS)” — which covers general regulatory announcements, compliance documents, and miscellaneous filings — this document best fits.
2025-10-29 Chinese
关于格列齐特缓释片获国家药监局签发药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the approval and issuance of a drug registration certificate by the National Medical Products Administration (NMPA) for a specific drug (Gliclazide Sustained Release Tablets). It includes details about the drug, its registration, and the impact on the company. The document is short (1152 characters) and serves as a regulatory announcement about a product approval rather than a financial report or detailed corporate filing. It does not contain financial data, management changes, or meeting materials. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-26 Chinese
持股5%以上股东拟减持股份的预披露公告（再次披露）
Major Shareholding Notification Classification · 95% confidence The document is a pre-disclosure announcement regarding a shareholder holding more than 5% of shares planning to reduce their holdings. It details the shareholder's identity, the number and percentage of shares to be reduced, the method and timing of the reduction, compliance with relevant laws, and risk warnings. There are no financial statements, earnings data, or management discussions. The document is a regulatory announcement about a planned shareholding reduction, which fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or earnings release.
2025-10-21 Chinese
独立董事提名人声明与承诺（温美琴）
Board/Management Information Classification · 95% confidence The document is a nomination statement and commitment declaration for an independent director candidate (温美琴) for 江苏德源药业股份有限公司. It details the qualifications, independence criteria, and compliance with relevant laws and regulations for the nominee. There are no financial statements, earnings data, or report attachments. The document is a formal announcement related to board/management changes, specifically the nomination of a new independent director. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and it is not a report publication announcement or certification. Hence, the classification is MANG with high confidence.
2025-10-13 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.